robust evidence specific to retatrutide's pharmacokinetic profile in this context is limited
Efficacy and Safety Endpoints Researchers Track Retatrutide trials track endpoints such as percentage body-weight change, HbA1c, waist circumference, lipids, systolic blood pressure, liver fat, adverse events, serious adverse events, and treatment discontinuation [4], [5], [6], [7], [9]
As of 2024, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA)
Seek prompt medical attention if you experience pain in the upper right abdomen, pain radiating to the shoulder, yellowing of the skin or eyes (jaundice), or fever alongside abdominal pain
Until the FDA reviews the full evidence and approves it, retatrutide wont be legally available as a prescription drug
Purchase five or more vials of the same product to receive 15% off